⚠️ Regulatory Notice
The compounds discussed in this article are intended for laboratory and research use only. They are not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. These compounds have not been evaluated by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. Both BPC-157 and TB-500 are prohibited substances under the World Anti-Doping Agency (WADA) Prohibited List.
BPC-157 TB-500 Stack: What the Preclinical Data Actually Shows
The BPC-157 TB-500 stack, widely nicknamed the “Wolverine stack,” is one of the most discussed peptide combinations in regenerative research. This guide examines the preclinical evidence, explores proposed synergy mechanisms, and outlines research-informed dosing ranges so you can evaluate this combination with clarity.
What Is the BPC-157 TB-500 Stack?
The BPC-157 TB-500 stack refers to the combined use of two regenerative peptides, Body Protection Compound-157 (BPC-157) and Thymosin Beta-4 fragment (TB-500), in coordinated research protocols. Each peptide has been independently studied for tissue repair, but the combination has gained significant attention due to proposed complementary mechanisms. The stack’s popularity exploded across biohacking communities, where anecdotal reports of accelerated recovery earned it the “Wolverine stack” nickname, a reference to the Marvel character’s legendary healing ability.
Understanding why researchers pair these two peptides requires a brief look at each compound’s research history. BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice, as detailed in a comprehensive review by Sikiric et al. (2011). TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein involved in cell migration and tissue repair, as described in research published in the Annals of the New York Academy of Sciences (2012). It is important to note that TB-500 and full-length Thymosin Beta-4 are not identical: TB-500 is a shorter synthetic peptide corresponding to the active region of the parent protein, and data on full-length Tβ4 does not automatically apply to the fragment.
The “Wolverine Stack” Origin Story
The term “Wolverine stack” emerged on Reddit and peptide forums around 2019 to 2020, coined by users reporting accelerated injury recovery when combining both peptides. The name spread rapidly because it captured the aspirational promise of the combination: multi-tissue healing that seemed almost superhuman. While the branding is rooted in internet culture rather than clinical science, the underlying research on each individual peptide is substantial and spans decades of preclinical investigation.
BPC-157: Body Protection Compound Overview
BPC-157 (also designated PL 14736) is a pentadecapeptide consisting of 15 amino acids. It is a partial sequence of body protection compound (BPC) isolated from human gastric juice. In animal models, BPC-157 has demonstrated effects on tendon, ligament, muscle, nerve, and gastrointestinal tissue repair. Researchers have noted its stability in human gastric juice, which is unusual for a peptide, and this has driven interest in multiple administration routes in preclinical work. For additional context on BPC-157’s preclinical research profile, see our BPC-157 research overview.
TB-500: Thymosin Beta-4 Fragment Overview
TB-500 is a synthetic version of the active region of Thymosin Beta-4 (Tβ4), a protein expressed in nearly all human and animal cell types. Tβ4’s primary biological role involves sequestering actin monomers (the building blocks of the cell’s structural scaffolding), which is critical for cell motility, migration, and differentiation. In research settings, TB-500 has been studied for its effects on wound healing, inflammation modulation, and cardiac tissue protection, although most of the published cardiac data is on the full-length parent protein Tβ4 rather than the TB-500 fragment specifically. Its mechanism is distinct from BPC-157’s, which is precisely why the combination interests researchers. For additional context on TB-500’s preclinical research profile, see our TB-500 research protocols guide.
How BPC-157 and TB-500 Work Together: The Synergy Mechanism
The rationale for combining BPC-157 and TB-500 stems from their distinct but complementary mechanisms of action. BPC-157 primarily operates through nitric oxide (NO) system modulation and growth factor upregulation, while TB-500 works through actin regulation and cell migration promotion. When researchers study these peptides individually, the healing pathways they activate overlap at critical junctures, particularly angiogenesis (new blood vessel formation) and inflammatory modulation, without competing for the same receptors.
It is essential to note that, as of January 2025, no peer-reviewed study has examined BPC-157 and TB-500 administered together in a controlled experiment. The “synergy” model is extrapolated from each peptide’s individual research profile. This is a significant caveat that separates research-informed stacking from clinically validated combination therapy.
Complementary Mechanisms of Action
BPC-157 interacts with the nitric oxide system, the FAK-paxillin pathway (a signaling cascade involved in cell adhesion and migration), and several growth factors including VEGF (vascular endothelial growth factor) and FGF (fibroblast growth factor). A 2019 review published in Current Pharmaceutical Design detailed how BPC-157 orchestrates multiple repair pathways simultaneously, a property researchers describe as “pleiotropic” (affecting multiple biological systems at once). TB-500, by contrast, primarily modulates actin polymerization and activates the Akt (protein kinase B) cell survival pathway. Note that most mechanistic data on actin modulation and Akt activation comes from studies on full-length Thymosin Beta-4, not the TB-500 fragment specifically.
- BPC-157 pathway: NO system → VEGF/FGF upregulation → angiogenesis + collagen deposition
- TB-500 pathway (based on Tβ4 data): Actin sequestration → cell migration → inflammatory cytokine modulation
- Convergence point: Both peptides independently promote angiogenesis through different upstream triggers
- Non-competing receptors: No known receptor overlap, which theoretically allows simultaneous activity
- Temporal distinction: BPC-157 research suggests rapid local action; TB-500 appears to act over longer systemic timelines
Angiogenesis and Blood Vessel Formation
Angiogenesis, the formation of new blood vessels from existing vasculature, is a cornerstone of tissue repair. Injured tissue requires increased blood supply to deliver oxygen, nutrients, and immune cells. Both BPC-157 and Thymosin Beta-4 have independently demonstrated pro-angiogenic properties in preclinical models, but through distinct molecular pathways. BPC-157 upregulates VEGF expression at the injury site, as shown in tendon healing research (Staresinic et al., 2018). Full-length Thymosin Beta-4 promotes endothelial cell migration, a prerequisite for vessel formation, through actin cytoskeleton reorganization. Whether the TB-500 fragment retains the same degree of pro-angiogenic activity as the full-length parent protein remains an open question in the literature.
Why Dual-Pathway Angiogenesis Matters in Research
The theoretical advantage of the BPC-157 TB-500 combination lies in activating angiogenesis from two directions simultaneously: BPC-157 signals the body to produce more vascular growth factors, while TB-500 (if it retains the parent protein’s properties) enables the endothelial cells themselves to physically migrate and form new vessel structures. In tissue repair research, this dual-pathway activation could potentially accelerate the vascularization timeline, though this hypothesis remains untested in controlled combination studies.
Growth Factor Modulation
Beyond angiogenesis, both peptides influence distinct growth factor cascades relevant to musculoskeletal repair. BPC-157 has been shown to upregulate growth hormone receptor expression in tendon fibroblasts, which may enhance the local effects of circulating growth hormone. Full-length Thymosin Beta-4, through its activation of the Akt pathway, promotes cell survival under stress conditions, reducing apoptosis (programmed cell death) in damaged tissue. Research into Thymosin Beta-4’s cardioprotective effects (Bock-Marquette et al., 2008) demonstrated this anti-apoptotic mechanism in cardiac tissue models. This finding applies to the full-length parent protein; equivalent cardioprotective data specific to the TB-500 fragment has not been published.
Research Application Insight
- Researchers studying multi-pathway tissue repair may find the complementary mechanisms of BPC-157 and TB-500 particularly relevant for designing comparative protocol studies.
- Purity of each individual peptide directly impacts experimental reproducibility when studying combination effects.
- Ensure each peptide in a stacking protocol has independent Certificate of Analysis documentation.
BPC-157 TB-500 Stack Protocol: Dosage, Timing & Cycles
Dosage parameters for the BPC-157 TB-500 stack are derived entirely from individual preclinical animal studies. No standardized human clinical trial dosing exists for either peptide alone or in combination. The ranges below reflect what has been used in published research on rat and mouse models, translated into commonly referenced microgram-per-kilogram frameworks. Researchers should approach these figures as preclinical reference points, not prescriptive protocols. For additional context on preclinical dosing parameters, see our BPC-157 preclinical dosing reference.
Research Dosage Ranges From Preclinical Studies
The most commonly cited BPC-157 research dosages in animal models range from 10 mcg/kg to 200 mcg/kg, administered intraperitoneally (IP, injection into the abdominal cavity) or locally near the injury site. For TB-500, preclinical studies have typically used dosages between 6 mg to 20 mg in equine models (where TB-500 research originated) and lower microgram-range doses in rodent studies. The table below summarizes key dosing parameters from published literature.
| Parameter | BPC-157 (Preclinical) | TB-500 (Preclinical) | Stack (Theoretical) |
|---|---|---|---|
| Typical dose range | 10 to 200 mcg/kg | 2 to 20 mg total (equine); lower in rodents | Each at individual study-level doses |
| Common admin routes | Intraperitoneal, subcutaneous, local | Subcutaneous, intramuscular | Subcutaneous (most referenced) |
| Frequency in studies | Daily or twice daily | Twice weekly (loading), weekly (maintenance) | Varies by protocol design |
| Study duration | 7 to 30 days typical | 4 to 8 weeks typical | 4 to 8 weeks (commonly referenced) |
| Stability note | Stable in gastric juice; heat-resistant | Requires reconstitution; cold storage | Reconstitute separately; store at 2 to 8 °C |
Timing and Administration in Research Models
In preclinical research, BPC-157 was typically administered at or near the time of injury induction, with daily dosing continuing through the observation period. TB-500 protocols in equine and rodent research generally follow a loading-and-maintenance pattern: higher-frequency dosing during the initial phase (often twice weekly for 2 to 4 weeks), followed by reduced frequency (once weekly). Researchers studying the combination often reference staggering administration times to observe independent and overlapping effects.
Cycle Length Considerations
Published BPC-157 studies range from 7-day acute injury models to 30-day chronic studies. TB-500 research typically spans 4 to 8 weeks to capture the full arc of tissue remodeling. When researchers reference BPC-157 TB-500 stack protocol durations, 4 to 8 weeks is the most commonly cited range in community-level discussions, though this lacks formal clinical validation. Research teams designing controlled experiments should calibrate cycle length to the specific tissue type and outcome being measured.
What the Research Shows: Key Study Findings
The evidence base for the BPC-157 TB-500 combination must be evaluated by examining each peptide’s independent research track record. While no published study has tested the combined stack, dozens of preclinical studies have investigated each compound’s effects on specific tissue types. The findings below represent the strongest areas of evidence for each peptide individually.
Tendon and Ligament Repair Studies
BPC-157 has shown some of its most consistent results in tendon healing models. A 2018 study by Staresinic and colleagues demonstrated that BPC-157 administration significantly improved Achilles tendon healing in rats, with increased collagen fiber organization and earlier restoration of biomechanical strength compared to controls. Thymosin Beta-4 (the parent molecule of TB-500) has also shown efficacy in connective tissue models, though the mechanism differs: Tβ4 promotes fibroblast migration to the injury site, while BPC-157 appears to enhance the quality of the collagen matrix being deposited.
Muscle and Soft Tissue Research
In muscle injury models, both peptides have demonstrated tissue-protective properties. BPC-157 accelerated muscle healing in crushed muscle models by promoting angiogenesis at the injury site and reducing fibrosis (excessive scar tissue formation). TB-500’s proposed contribution to muscle repair appears to center on anti-inflammatory effects and promotion of satellite cell activation (the precursor cells responsible for muscle fiber regeneration), based primarily on data from the parent protein Thymosin Beta-4.
The Scar Tissue Variable
One of the most compelling aspects of BPC-157 research is the observation that treated tissues show improved organizational quality, meaning less disordered scar tissue and more functional tissue architecture. This finding has been replicated across multiple tissue types in animal models and represents a particularly relevant data point for researchers interested in tissue quality rather than simply tissue volume.
Gastrointestinal and Systemic Findings
BPC-157’s origin in gastric juice research provides a unique dimension to its profile. Studies have demonstrated its protective effects on gastric mucosal lining in various injury and inflammation models. This gastrointestinal connection is relevant because many researchers exploring multi-peptide protocols are also investigating gut-systemic axis interactions. TB-500’s systemic distribution pattern, reaching tissues far from the injection site, may complement BPC-157’s potentially more localized action profile, though direct comparative pharmacokinetic data for the two peptides used together has not been published.
⚠️ 5 Important Research Considerations for the BPC-157 TB-500 Stack
Understanding these limitations is essential for designing valid experiments and interpreting results accurately.
- No published combination studies: As of January 2025, no peer-reviewed study has tested BPC-157 and TB-500 together in a controlled experiment. All synergy claims are extrapolated from individual compound research.
- Animal model translation gaps: The majority of BPC-157 and TB-500 evidence comes from rodent and equine models. Dose translation, pharmacokinetics, and tissue-specific responses may differ significantly across species. Allometric scaling (the mathematical adjustment of doses between species based on body surface area, not just body weight) is required but introduces its own assumptions.
- Purity variability across suppliers: Unverified peptide sources may contain impurities, truncated sequences, or misidentified compounds that fundamentally compromise experimental validity. HPLC verification and Certificate of Analysis documentation are non-negotiable for credible research.
- Regulatory status: Neither BPC-157 nor TB-500 is FDA-approved for any human therapeutic use. The FDA’s bulk drug compounding framework has created additional regulatory complexity for peptide sourcing. The FDA’s concerns with compounded peptides focus primarily on manufacturing quality issues (contamination, potency variability, sterility failures at compounding facilities), which are distinct from questions about the pharmacology of the peptide molecules themselves. Both BPC-157 and TB-500 also appear on the World Anti-Doping Agency (WADA) Prohibited List under the peptide hormones and growth factors category. These peptides are sold for laboratory and research use only.
- Anecdotal bias: Much of the “Wolverine stack” narrative is driven by self-reported user experiences on forums and social media. Positive-outcome bias, placebo effects, and concurrent interventions (physical therapy, other supplements) confound these reports significantly.
Consequence Examples
Issue: Using peptides without Certificate of Analysis. Research Impact: Unknown purity introduces uncontrolled variables, making results unreproducible and unpublishable.
Issue: Extrapolating rodent doses directly to larger organisms. Research Impact: Allometric scaling errors can produce doses that are subtherapeutic or excessively high, invalidating the experiment.
“The absence of controlled combination data means that any ‘BPC-157 TB-500 stack protocol’ should be approached as a hypothesis to be tested, not a validated treatment regimen.”
Sourcing research-grade peptides with verified purity documentation reduces these variables significantly. View Phoenix Peptide Labs quality standards →
Key Preclinical Findings: Individual BPC-157 and TB-500 Research
While the combination lacks dedicated clinical investigation, the individual evidence base for each peptide provides a credible foundation for future stacking research. These principles emerge from the most consistent preclinical findings. Unless noted, TB-500 findings below are based on research on the full-length parent protein Thymosin Beta-4.
Research backing: Seiwerth et al., BPC-157 mechanisms review, Current Pharmaceutical Design, 2019
Researchers who apply these principles, pairing high-purity peptides with rigorous experimental design, consistently report more reproducible results and greater confidence in their data.
How to Source High-Quality BPC-157 TB-500 Stack Peptides for Your Research
Sourcing research-grade BPC-157 and TB-500 requires verifying purity via independent HPLC testing, confirming amino acid sequence identity through mass spectrometry, and obtaining a Certificate of Analysis for each batch. Peptide quality directly determines experimental validity, particularly in multi-peptide stack protocols where impurities in one compound can confound results attributed to the other.
The difference between credible stack research and wasted resources often comes down to sourcing discipline. When two peptides are combined, quality failures in either compound don’t just weaken results; they make it impossible to determine which peptide (or which impurity) produced the observed effect.
HPLC Purity Verification
High-performance liquid chromatography (HPLC) remains the gold standard for confirming peptide purity. For BPC-157 TB-500 stack research, each peptide should independently demonstrate ≥98% purity by HPLC, with the chromatogram available for review. Lower purity grades introduce unknown peptide fragments, synthesis byproducts, and potential bioactive contaminants that create uncontrolled variables in any experiment.
Researchers should request HPLC data that shows both the purity percentage and the retention time, confirming the correct compound is present at the stated concentration. Batch-specific chromatograms are more reliable than generic product-level claims.
Certificate of Analysis Documentation
A Certificate of Analysis (COA) is not optional; it is the minimum documentation standard for any research-grade peptide purchase. A credible COA should include the peptide’s molecular weight (confirmed by mass spectrometry), HPLC purity, amino acid sequence, appearance, solubility, and endotoxin levels. For a BPC-157 TB-500 combination protocol, you need a separate COA for each peptide, referencing the specific batch you are purchasing.
Be cautious of suppliers who provide “sample” COAs that don’t match the batch number on the vial. This is one of the most common red flags in the research peptide market.
Lyophilization and Storage Quality
Both BPC-157 and TB-500 are supplied as lyophilized (freeze-dried) powders. Proper lyophilization ensures structural integrity during shipping and storage. Once reconstituted, both peptides require refrigeration at 2 to 8 °C and should typically be used within a defined timeframe to maintain potency. For wolverine healing stack research, storing each peptide separately and reconstituting only the amount needed for immediate use helps preserve peptide integrity across multi-week protocols.
Ready to source research-grade peptides for your stack protocol? Shop Phoenix Peptide Labs’ verified peptide catalog →
Sterility Testing for Injectable Research Preparations
Research peptides prepared for parenteral (injectable) administration in preclinical models require sterility assurance. Sterility testing should be documented on the COA or available upon request. Endotoxin testing via LAL assay (Limulus amebocyte lysate, a test that detects bacterial endotoxin contamination) is particularly critical. Bacterial endotoxin contamination in research peptides can trigger inflammatory responses that confound tissue repair observations, which is especially problematic in healing-focused stack research.
Why Peptide Grade Matters for Stack Research
In single-peptide research, an impurity may produce a measurable artifact. In multi-peptide stack research, it creates exponentially more confounding variables. If BPC-157 contains a truncated sequence impurity, and TB-500 contains a synthesis-related acetylation byproduct, the researcher now has four compounds in the experimental system: two intended and two unknown. This makes it functionally impossible to attribute observed effects to the stack itself.
Research-grade sourcing isn’t a premium; it’s a prerequisite for publishable, reproducible data.
Phoenix Peptide Labs Quality Assurance
Every peptide from Phoenix Peptide Labs is manufactured and tested to meet rigorous research-grade standards.
BPC-157 TB-500 Stack: Research Application Comparison
Understanding when each peptide, and the combination, is most relevant requires mapping research applications side by side. The comparison table below summarizes key differentiators across the most studied tissue types and mechanisms, helping researchers identify where the BPC-157 TB-500 combination may offer the greatest theoretical advantage over individual peptide use. Note that TB-500 data in this table draws substantially from studies on full-length Thymosin Beta-4 (the parent protein).
| Research Parameter | BPC-157 Alone | TB-500 / Tβ4 Data | Stack (Theoretical) |
|---|---|---|---|
| Primary mechanism | NO system / VEGF upregulation | Actin regulation / cell migration (Tβ4 data) | Dual-pathway activation (theoretical) |
| Tendon/ligament repair | Strong evidence (multiple studies) | Moderate evidence (primarily Tβ4) | Highest theoretical coverage |
| Muscle tissue | Demonstrated in crush models | Satellite cell activation (Tβ4 data) | Complementary mechanisms (theoretical) |
| Cardiac tissue | Limited but positive data | Strong cardioprotective evidence for Tβ4 (parent molecule, not TB-500 specifically) | Tβ4-dominant application |
| GI / mucosal | Strong evidence (original research area) | Limited data | BPC-157-dominant application |
| Anti-inflammatory | Cytokine modulation observed | Cytokine modulation observed (Tβ4 data) | Dual anti-inflammatory pathways (theoretical) |
| Angiogenesis | VEGF/FGF-mediated | Endothelial cell migration (Tβ4 data) | Convergent dual-pathway (theoretical) |
| Systemic vs. local | Primarily local (near admin site) | More systemic distribution | Local + systemic coverage (theoretical) |
Who Uses the BPC-157 TB-500 Stack in Research?
The BPC-157 TB-500 combination attracts a diverse range of researchers and research-adjacent professionals, each approaching the stack from different angles and with different quality requirements.
The Preclinical Research Team
University or private-sector teams running controlled animal studies on multi-peptide tissue repair protocols. They need batch-specific COAs, consistent purity across multi-week study durations, and documented sterility for injectable preparations.
The Independent Researcher Prioritizing Purity
Self-funded researchers studying peptide healing mechanisms who understand that budget suppliers often cut corners on synthesis quality. They’re willing to invest more per milligram for verified purity because unreliable results waste more money than premium peptides cost.
Have questions about your research needs? Contact our team →
The Lab Purchasing Agent Scaling Supply
Procurement professionals responsible for sourcing consistent, documented research-grade peptides across multiple ongoing studies. They need reliable supply chains, volume pricing transparency, and compliance documentation that satisfies institutional review requirements.
Frequently Asked Questions
The BPC-157 TB-500 stack combines two regenerative peptides that activate distinct but complementary tissue repair pathways. BPC-157 works primarily through nitric oxide system modulation and VEGF upregulation, while TB-500 (based on its parent protein Thymosin Beta-4) promotes cell migration via actin regulation and activates the Akt cell survival pathway. The combination is theorized to provide broader tissue repair coverage than either peptide alone, though this hypothesis is based on individual peptide studies, not published combination research. For sourcing questions or documentation requests, contact our team.
Preclinical BPC-157 studies typically use 10 to 200 mcg/kg, while TB-500 research uses variable doses depending on the animal model. No standardized dosing protocol exists for the combination in any species. All dosing references in community forums are extrapolated from individual peptide animal studies and should be treated as unvalidated reference points. Researchers should design dose-response curves appropriate to their specific model organism and tissue target. For additional context on preclinical dosing parameters, see our TB-500 preclinical dosing reference. For sourcing questions or documentation requests, contact our team.
No known receptor competition has been identified between BPC-157 and TB-500 in published research. Their distinct mechanisms of action, with BPC-157 acting through the NO/VEGF axis and TB-500 through actin/Akt pathways, suggest no pharmacological contraindication to concurrent use in research models. However, many researchers studying the combination in preclinical settings stagger administration times to isolate individual peptide contributions and observe temporal interaction effects. For sourcing questions or documentation requests, contact our team.
Published BPC-157 studies range from 7 to 30 days, while TB-500 research typically spans 4 to 8 weeks. The most commonly referenced stack protocol duration in research communities is 4 to 8 weeks, calibrated to tissue remodeling timelines. Longer cycles may be appropriate for chronic injury models, while shorter protocols suit acute tissue injury studies. Cycle length should be determined by the specific tissue type, injury model, and measurable endpoints of the research design. For sourcing questions or documentation requests, contact our team.
Need technical specifications or purity documentation? Contact Phoenix Peptide Labs directly →
“Wolverine stack” is an informal name for the BPC-157 and TB-500 combination, coined on Reddit and peptide forums around 2019 to 2020. The name references the Marvel character Wolverine’s rapid healing ability. Users who reported accelerated injury recovery began using the term, and it spread across biohacking and fitness communities. While the branding is culturally compelling, it is important to recognize that the name reflects community enthusiasm rather than clinical validation. The underlying individual peptide research is substantial, but the combination remains unvalidated in controlled studies. For deeper research context, explore Phoenix Peptide Labs’ research library.
Research-grade peptides should demonstrate ≥98% purity by HPLC for credible experimental results. In multi-peptide stack protocols, purity requirements are arguably more critical than in single-compound studies because impurities in either peptide create additional unknown variables. Each peptide should have an independent batch-specific Certificate of Analysis confirming purity, molecular identity (via mass spectrometry), endotoxin levels, and sterility status. As noted in a 2015 review of Thymosin Beta-4 research (which covers the parent molecule of TB-500), standardized peptide quality is fundamental to reproducible results across laboratories. For sourcing questions, contact our team.
No. Neither BPC-157 nor TB-500 is approved by the FDA for human therapeutic use. Both peptides are classified for research and laboratory use only. While preclinical evidence is extensive and spans multiple tissue types, no completed human clinical trial has validated either peptide, alone or in combination, for any medical condition. Both compounds also appear on the World Anti-Doping Agency (WADA) Prohibited List. Regulatory developments continue to evolve, and researchers should monitor FDA guidance on peptide compounding and scheduling. All Phoenix Peptide Labs products are sold strictly for laboratory and research purposes. For sourcing questions or documentation requests, contact our team.
⚗️ Research Use Disclaimer
All content on this page is intended for informational and research purposes only. The compounds discussed are not approved by the FDA for human or veterinary therapeutic use. These compounds have not been evaluated by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed medical professional before making any health-related decisions. Phoenix Peptide Labs products are sold strictly for laboratory and research use.